Literature DB >> 25044669

Neonatal medical exposures and characteristics of low birth weight hepatoblastoma cases: a report from the Children's Oncology Group.

Lucie M Turcotte1, Michael K Georgieff, Julie A Ross, James H Feusner, Gail E Tomlinson, Marcio H Malogolowkin, Mark D Krailo, Nicole Miller, Rachel Fonstad, Logan G Spector.   

Abstract

BACKGROUND: Hepatoblastoma is a malignancy of young children. Low birth weight is associated with significantly increased risk of hepatoblastoma and neonatal medical exposures are hypothesized as contributors. This study represents the largest case-control study of hepatoblastoma to date and aimed to define the role of neonatal exposures in hepatoblastoma risk among low birth weight children. PROCEDURE: Incident hepatoblastoma cases who were born <2,500 g (N = 60), diagnosed between 2000 and 2008, were identified through the Children's Oncology Group. Controls were recruited through state birth registries (N = 51). Neonatal medical exposures were abstracted from medical records. Subjects from the Vermont Oxford Network were used for further comparisons, as were existing reports on neonatal medical exposures.
RESULTS: Case-control comparisons were hindered by poor matching within birth weight strata. Cases were smaller and received more aggressive neonatal treatment compared to controls, and reflected high correlation levels between birth weight and treatments. Similar difficulty was encountered when comparing cases to Vermont Oxford Network subjects; cases were smaller and required more aggressive neonatal therapy. Furthermore, it appears hepatoblastoma cases were exposed to a greater number of diagnostic X-rays than in case series previously reported in the neonatal literature.
CONCLUSIONS: This study presents the largest case series of hepatoblastoma in <2,500 g birth weight infants with accompanying neonatal medical exposure data. Findings confirm that birth weight is highly correlated with exposure intensity, and neonatal exposures are themselves highly correlated, which hampers the identification of a causal exposure among hepatoblastoma cases. Experimental models or genetic susceptibility testing may be more revealing of etiology.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  NICU; case-control study; exposure; hepatoblastoma; low birth weight

Mesh:

Year:  2014        PMID: 25044669      PMCID: PMC4287257          DOI: 10.1002/pbc.25128

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  34 in total

1.  Effects of gestation and birth weight on the growth and development of very low birthweight small for gestational age infants: a matched group comparison.

Authors:  T Gutbrod; D Wolke; B Soehne; B Ohrt; K Riegel
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2000-05       Impact factor: 5.747

2.  Parental infertility, infertility treatment and hepatoblastoma: a report from the Children's Oncology Group.

Authors:  Susan E Puumala; Julie A Ross; James H Feusner; Gail E Tomlinson; Marcio H Malogolowkin; Mark D Krailo; Logan G Spector
Journal:  Hum Reprod       Date:  2012-04-03       Impact factor: 6.918

3.  Case-control study of perinatal factors and hepatoblastoma in children with an extremely low birthweight.

Authors:  K Maruyama; H Ikeda; T Koizumi; Y Tsuchida; M Tanimura; H Nishida; N Takahashi; M Fujimura; Y Tokunaga
Journal:  Pediatr Int       Date:  2000-10       Impact factor: 1.524

4.  Hepatoblastoma in children of extremely low birth weight: a report from a single perinatal center.

Authors:  Takaharu Oue; Akio Kubota; Hiroomi Okuyama; Hisayoshi Kawahara; Keigo Nara; Keisei Kawa; Hiroyuki Kitajima
Journal:  J Pediatr Surg       Date:  2003-01       Impact factor: 2.545

5.  Hepatoblastoma in the Nordic countries.

Authors:  S de Fine Licht; L S Schmidt; N H Rod; K Schmiegelow; P M Lähteenmäki; P Kogner; C Träger; T Stokland; J Schüz
Journal:  Int J Cancer       Date:  2012-01-03       Impact factor: 7.396

6.  Epidemiology of primary hepatic malignancies in U.S. children.

Authors:  Anil Darbari; Keith M Sabin; Craig N Shapiro; Kathleen B Schwarz
Journal:  Hepatology       Date:  2003-09       Impact factor: 17.425

7.  Maternal pregnancy events and exposures and risk of hepatoblastoma: a Children's Oncology Group (COG) study.

Authors:  Jessica R B Musselman; Michael K Georgieff; Julie A Ross; Gail E Tomlinson; James Feusner; Mark Krailo; Logan G Spector
Journal:  Cancer Epidemiol       Date:  2013-01-09       Impact factor: 2.984

8.  Infant mortality and low birth weight among black and white infants--United States, 1980-2000.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2002-07-12       Impact factor: 17.586

9.  A standardized nutrition approach for very low birth weight neonates improves outcomes, reduces cost and is not associated with increased rates of necrotizing enterocolitis, sepsis or mortality.

Authors:  T J Butler; L J Szekely; J L Grow
Journal:  J Perinatol       Date:  2013-06-13       Impact factor: 2.521

10.  Birth characteristics and hepatoblastoma risk in young children.

Authors:  Peggy Reynolds; Kevin Y Urayama; Julie Von Behren; James Feusner
Journal:  Cancer       Date:  2004-03-01       Impact factor: 6.860

View more
  7 in total

Review 1.  Genetic and nongenetic risk factors for childhood cancer.

Authors:  Logan G Spector; Nathan Pankratz; Erin L Marcotte
Journal:  Pediatr Clin North Am       Date:  2014-10-18       Impact factor: 3.278

2.  Hepatoblastoma modeling in mice places Nrf2 within a cancer field established by mutant β-catenin.

Authors:  Sarah A Comerford; Elizabeth A Hinnant; Yidong Chen; Hima Bansal; Shawn Klapproth; Dinesh Rakheja; Milton J Finegold; Dolores Lopez-Terrada; Kathryn A O'Donnell; Gail E Tomlinson; Robert E Hammer
Journal:  JCI Insight       Date:  2016-10-06

3.  Maternal and paternal occupational exposures and hepatoblastoma: results from the HOPE study through the Children's Oncology Group.

Authors:  Amanda E Janitz; Gurumurthy Ramachandran; Gail E Tomlinson; Mark Krailo; Michaela Richardson; Logan Spector
Journal:  J Expo Sci Environ Epidemiol       Date:  2017-03-08       Impact factor: 5.563

4.  Maternal Preeclampsia and Odds of Childhood Cancers in Offspring: A California Statewide Case-Control Study.

Authors:  Xiaoqing Xu; Beate Ritz; Myles Cockburn; Christina Lombardi; Julia E Heck
Journal:  Paediatr Perinat Epidemiol       Date:  2017-01-26       Impact factor: 3.980

5.  Insights Into the Somatic Mutation Burden of Hepatoblastomas From Brazilian Patients.

Authors:  Talita Ferreira Marques Aguiar; Maria Prates Rivas; Silvia Costa; Mariana Maschietto; Tatiane Rodrigues; Juliana Sobral de Barros; Anne Caroline Barbosa; Renan Valieris; Gustavo R Fernandes; Debora R Bertola; Monica Cypriano; Silvia Regina Caminada de Toledo; Angela Major; Israel Tojal; Maria Lúcia de Pinho Apezzato; Dirce Maria Carraro; Carla Rosenberg; Cecilia Maria Lima da Costa; Isabela W Cunha; Stephen Frederick Sarabia; Dolores-López Terrada; Ana Cristina Victorino Krepischi
Journal:  Front Oncol       Date:  2020-05-05       Impact factor: 6.244

6.  Unraveling the Genetic Architecture of Hepatoblastoma Risk: Birth Defects and Increased Burden of Germline Damaging Variants in Gastrointestinal/Renal Cancer Predisposition and DNA Repair Genes.

Authors:  Talita Aguiar; Anne Teixeira; Marília O Scliar; Juliana Sobral de Barros; Renan B Lemes; Silvia Souza; Giovanna Tolezano; Fernanda Santos; Israel Tojal; Monica Cypriano; Silvia Regina Caminada de Toledo; Eugênia Valadares; Raquel Borges Pinto; Osvaldo Afonso Pinto Artigalas; Joaquim Caetano de Aguirre Neto; Estela Novak; Lilian Maria Cristofani; Sofia M Miura Sugayama; Vicente Odone; Isabela Werneck Cunha; Cecilia Maria Lima da Costa; Carla Rosenberg; Ana Krepischi
Journal:  Front Genet       Date:  2022-04-12       Impact factor: 4.772

7.  Analysis of factors related to recurrence of paediatric hepatoblastoma - a single Centre retrospective study.

Authors:  Wei Yang; Yiwei Chen; Yijin Huang; Huanmin Wang
Journal:  BMC Pediatr       Date:  2019-12-10       Impact factor: 2.125

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.